Modulation of resistance to anti-APO-1-induced apoptosis in osteosarcoma cells by cytokines

International Journal of Cancer

Volumn 72, Issue 3, 1997, Pages 536-542

  Fellenberg, Joerg ^a   Mau, Hans ^a   Scheuerpflug, Christian ^a   Ewerbeck, Volker ^a   Debatin, Klaus Michael ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOHEXIMIDE; DACTINOMYCIN; FAS ANTIGEN; GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; OSTEOSARCOMA; PRIORITY JOURNAL; RNA SPLICING;

ANTIBODIES; ANTIGENS, CD95; APOPTOSIS; BLOTTING, WESTERN; CULTURE MEDIA, CONDITIONED; CYTOKINES; HUMANS; INTERFERON TYPE II; OSTEOBLASTS; OSTEOSARCOMA; POLYMERASE CHAIN REACTION; RNA SPLICING; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030796003     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19970729)72:3<536::AID-IJC25>3.0.CO;2-8     Document Type: Article

References (41)

1. CASCINO, I., FIUCCI, G., PAPOFF, G. and RUBERTI, G., Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J. Immunol., 154, 2706-2713 (1995).
2. CASCINO, I., PAPOFF, G., DE MARIA, R., TESTI, R. and RUBERTI, G., Fas/Apo-1 (CD95) receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediated apoptosis. J. Immunol., 156, 13-17 (1996).
3. CHENG, J., ZHOU, T., LIU, C., SHAPIRO, J.P., BRAUER, M.J., KIEFER, M.C., BARR, P.J. and MOUNTZ, J.D., Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science, 263, 1759-1762 (1994).
4. COHEN, P.L. and EISENBERG, R.A., Lpr and gld. Single gene models of systemic autoimmunity lymphoproliferative disease. Ann. Rev. Immunol., 9, 243-269 (1991).
5. DEBATIN, K.-M., Disturbances of the CD95 (APO-1/Fas) system in disorders of lymphohaematopoietic cells. Cell Death Differentiation, 3, 185-189 (1996).
6. DEBATIN, K.-M., GOLDMANN, C.K., BAMFORD, R., WALDMANN, T.A. and KRAMMER, P.M., Monoclonal antibody mediated apoptosis in adult T cell leukaemia. Lancet, 335, 497-500 (1990).
7. DEBATE, K.-M., GOLDMAN, C.K., WALDMAN, T.A. and KRAMMER, P.H., APO-1-induced apoptosis of leukemia cells from patients with adult T-cell leukemia. Blood, 81, 2972-2977 (1993).
8. DEBATIN, K.-M. and KRAMMER, P.M., Resistance to APO-1 (CD95) induced apoptosis in T-ALL is determined by a BCL-2 independent anti-apoptotic program. Leukemia, 9, 815-820 (1995).
9. DEBATIN, K.-M., SÜSS, D. and KRAMMER, P.H., Differential expression of APO-1 on human thymocytes: implications for negative selection. Europ. J. Immunol., 24, 753-758 (1994).
10. FALK, M.H., TRAUTH, B.C., DEBATIN, K.-M., KLAS, C., GREGORY, C.D., RICKINSON, A.B., CALENDER, A., LENOIR, G.M., ELLWART, J.W., KRAMMER, P.H. and BORNKAMM, G.W., Expression of the APO-1 antigen in Burkitt lymphoma cell lines correlates with a shift toward a lymphoblastoid phenotype. Blood, 79, 3300-3306 (1992).
11. FISHER, G.H., ROSHNBERG, F.J., STRAUS, S.E., DALE, J.K., MIDDELTON, L.A., LIN, A.Y., STROBER, W., LENARDO, M.J. and PUCK, J.M., Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell, 81, 935-946 (1995).
12. FRIESEN, C., HERR, I., KRAMMER, P.H. and DEBATIN, K.-M., Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nature (Med.), 2, 574-577 (1996).
13. ITOH, N. and NAGATA, S., A novel protein domain required for apoptosis. J. biol. Chem., 268, 10932-10937 (1993).
14. ITOH, N., YONEHARA, S., ISHII, A., YONEHARA, M., MIZUSHIMA, S.-I., SAMESHIMA, M., HASE, A., SETO, Y. and NAGATA, S., The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell, 66, 233-243 (1991).
15. KAGI, D., VIGNAUX, F., LEDERMANN, B., BURKI, K., DEPRAETERE, V., NAGATA, S., HENGARTNER, H. and GOLSTEIN, P., Fas and perform pathways as major mechanisms of T-cell-mediated cytotoxicity. Science, 265, 528- 530 (1994).
16. KISCHKEL, F.C., HELLBARDT, S., BEHRMANN, I., GERMER, M., PAWLITA, M., KRAMMER, P.H. and PETER, M.E., Cytotoxicity-dependent APO-1 (Fas/ CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J., 14, 5579-5588 (1995).
17. KLAS, C. DEBATIN, K.-M., JONKER, R.R. and KRAMMER, P.M., Activation interferes with the APO-1 pathway in mature human T cells. Int. Immunol., 5, 625-630 (1993).
18. KNIPPING, E., DEBATIN, K.-M., STRICKER, K., HEILIG, B., EDER, A. and KRAMMER, P.H., Identification of soluble APO-1 in supernatants of human B- and T-cell lines and increased scrum levels in B- and T-cell leukemias. Blood, 85, 1562-1569 (1995).
19. KOOPMAN, G., REUTELINGSPERGER, C.P.M., KUIJTEN, G.A.M., KEEHNEN, R.M.J., PALS, S.T. and VAN OERS, M.H.J., Annexin V for How cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood, 84, 1415-1420 (1994).
20. LEITHÄUSER, F., DHEIN, J., MECHTERSHEIMER, G., KORETZ, K., BRÜDERLEIN, S., HENNE, C., SCHMIDT, A., DEBATIN, K.-M., KRAMMER, P.H. and MÖLLER, P., Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab. Invest., 69, 415-429 (1993).
21. MIDIS, G.P., SHEN, Y. and OWEN-SCHAUB, L.B., Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy. Cancer Res., 56, 3870- 3874 (1996).
22. MÖLLER, P., HENNE, C., LEITHÄUSER, F., EICHELMANN, A., SCHMIDT, A., BR ÜDERLEIN, S., DHEIN, J. and KRAMMER, P.M., Coregulation of the APO-1 antigen with intercellular adhesion molecule-1 (CD 54) in tonsillar B cells and coordinate expression in follicular center B cells and in follicle center and mediastinal B-cell lymphomas. Blood, 81, 2067-2075 (1993).
23. NI, R., TOMITA, Y., MATSUDA, K., ICHIHARA, A., ISHIMURA, K., OGASAWARA, J. and NAGATA, S., Fas-mediated apoptosis in primary cultured mouse hepatocytes. Exp. Cell Res., 215, 332-337 (1994).
24. NICOLETTI, I., MIGLIORATI, G., PAGLIACCI, M.C., GRIGNANI, F. and RICCARDI, C., A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods, 139, 271-279 (1991).
25. OEHM, A., BEHRMANN, I., FALK, W., PAWLITA, M., MAIER, G., KLAS, C., LI-WEBER, M., RICHARDS, S., DHEIN, J., TRAUTH, B.C., PONSTINGL, H. and KRAMMER, P.M., Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. J. biol. Chem., 267, 10709-10715 (1992).
26. OWEN-SCHAUB, L.B., ANGELO, L.S., RADINSKY, R., WARE, C.F., GESNER, T.G. and BARTOS, D.P., Soluble Fas/APO-1 in tumor cells: a potential regulator of apoptosis? Cancer Lett., 94, 1-8 (1995).
27. OWEN-SCHAUB, L.B., METERISSIAN, S. and FORD, R.J., Fas/APO-1 expression and function on malignant cells of hematologic and nonhematologic origin. J. Immunother., 14, 234-241 (1993).
28. OWEN-SCHAUB, L.B., RADINSKY, R., KRUZEL, E., BERRY, K. and YONEHARA, S., Anti-Fas on nonhematopoietic tumors: levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness. Cancer Res., 54, 1580- 1586 (1994).
29. PAPOFF, G., CASCINO, I., ERAMO, A., STARACE, G., LYNCH, D.H. and RUBERTI, G., An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro. J. Immunol., 156, 4622-1630 (1996).
30. PETER, M.E., KISCHKEL, F.C., HELLBARDT, S., CHINNAIYAN, A.M., KRAMMER, P.H. and DIXIT, V.M., CD95 (APO-l/Fas)-associating signalling proteins. Cell Death Differentiation, 3, 161-170 (1996).
31. RAFF, M.C., Social controls on cell survival and cell death. Nature (Lond.), 356, 397-400 (1992).
32. RIEUX-LAUCAT, F., LE DEIST, F., HIVROZ, C., ROBERTS, I.A.G., DEBATIN, K.-M., FISCHER, A. and DE VILLARTAY, J.P., Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science, 268, 1347-1349 (1995).
33. SCHULZE-OSTHOFF, K., BAUER, M.K.A., VOGT, M. and LOS, M., Role of ICE-related and other proteases in Fas-mediated apoptosis. Cell Death Differentiation, 3, 177-184 (1996).
34. + T-cell-mediated cytotoxity. J. Immunol., 152, 1127-1133 (1994).
35. SUDA, T., TAKAHASHI, T., GOLSTEIN, P. and NAGATA, S., Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell, 75, 1169-1178 (1993).
36. TAKAHASHI, T., TANAKA, M., BRANNAN, C.I., JENKINS, N.A., COPELAND, N.G., SUDA, T. and NAGATA, S., Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell, 76, 969-976 (1994).
37. TAKAHASHI, T., TANAKA, M., INAZAWA, J., ABE, T., SUDA, T. and NAGATA, S., Human Fas ligand: gene structure, chromosomal location and species specificity. Int. Immunol., 6, 1567-1574 (1994).
38. TRAUTH, B.C., KLAS, C. PETERS, A.M.J., MATZKU, S., MÖLLER, R. FALK, W., DEBATIN, K.-M. and KRAMMER, P.H., Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science, 245, 301-305 (1989).
39. WATANABE-FUKUNAGA, R., BRANNAN, C.I., COPELAND, N.G., JENKINS, N.A. and NAGATA, S., Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature (Lond.), 356, 314-317 (1992).
40. WELLER, M., FREI, K., GROSCURTH, P., KRAMMER, P.H., YONEKAWA, Y. and FONTANA, A., Anti-Fas/APO-1 antibody mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines. J. clin. Invest., 94, 954-964 (1994).
41. WYLLIE, A.H., KERR, J.F.R. and CURRIE, A.R., Cell death: the significance of apoptosis. Int. Rev. Cytol., 68, 251-306 (1980).